Patents by Inventor Risto Lammintausta
Risto Lammintausta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10626140Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.Type: GrantFiled: December 22, 2015Date of Patent: April 21, 2020Assignee: Forendo Pharma LTDInventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
-
Publication number: 20200060991Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: November 1, 2019Publication date: February 27, 2020Inventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Patent number: 10500166Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: GrantFiled: March 21, 2013Date of Patent: December 10, 2019Assignee: QUATRX PHARMACEUTICALSInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Patent number: 10413557Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: December 22, 2015Date of Patent: September 17, 2019Assignee: FORENDO PHARMA LTD.Inventors: Leena Hirvelä, Pasi Koskimies, Risto Lammintausta, Marjo Hakola, Maire Eloranta
-
Patent number: 10377791Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: August 13, 2019Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20180265541Abstract: The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.Type: ApplicationFiled: December 22, 2015Publication date: September 20, 2018Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
-
Patent number: 9850272Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: December 26, 2017Assignee: FORENDO PHARMA LTD.Inventors: Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170354664Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 22, 2015Publication date: December 14, 2017Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Pasi KOSKIMIES, Risto Lammintausta, Marjo HAKOLA, Maire ELORANTA
-
Patent number: 9663549Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 25, 2014Date of Patent: May 30, 2017Assignee: FORENDO PHARMA LTD.Inventors: Maire Eloranta, Leena Hirvelä, Lauri Kangas, Pasi Koskimies, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170114090Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: April 27, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto Lammintausta, Mikko Unkila
-
Publication number: 20170081357Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Maire ELORANTA, Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
-
Publication number: 20170081356Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 25, 2014Publication date: March 23, 2017Applicant: FORENDO PHARMA LTDInventors: Leena HIRVELÄ, Lauri KANGAS, Pasi KOSKIMIES, Risto LAMMINTAUSTA, Mikko UNKILA
-
Publication number: 20130217696Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: March 21, 2013Publication date: August 22, 2013Applicant: QuatRX Pharmaceuticals CompanyInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20100261729Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: June 8, 2010Publication date: October 14, 2010Applicant: QUATRX PHARMACEUTICALS COMPANYInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20080312239Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: June 13, 2008Publication date: December 18, 2008Applicant: QUATRX PHARMACEUTICALS COMPANYInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20060293294Abstract: This invention relates to a method for the treatment or prevention of androgen deficiency in a male individual by administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof. Furthermore, the invention concerns methods for the treatment or prevention of diseases or disorders caused by androgen deficiency.Type: ApplicationFiled: July 18, 2005Publication date: December 28, 2006Applicant: HORMOS MEDICAL CORPORATIONInventors: Taru Blom, Janne Komi, Risto Lammintausta
-
Publication number: 20050187302Abstract: This invention relates to a method for the treatment or prevention of osteoporosis in an individual suffering from increased bone turnover, said method comprising administering to said individual an effective amount of a therapeutically active compound, which is a selective estrogen receptor modulator of the triphenylalkene or triphenylalkane structure.Type: ApplicationFiled: February 23, 2004Publication date: August 25, 2005Applicant: Hormos Medical CorporationInventors: Taru Blom, Lauri Kangas, Risto Lammintausta
-
Patent number: 6875775Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C?CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and ?R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 5, 2005Assignee: Hormos Medical Oy LTDInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen, Arto Karjalainen
-
Patent number: 6723738Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2 , which are the same or different are a) H, halogen, OCH3, OH; or where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH2C≡CH or —CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH2)nCH2—O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH2CH2OH, or —CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH3; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.Type: GrantFiled: April 8, 2003Date of Patent: April 20, 2004Assignee: Hormos Medical Oy LtdInventors: Marja-Liisa Södervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Härkönen, Kalervo Väänänen
-
Publication number: 20030225130Abstract: The invention provides novel selective estrogen receptor modulator compounds of the general formula: 1Type: ApplicationFiled: April 8, 2003Publication date: December 4, 2003Applicant: HORMOS MEDICAL OY LTD.Inventors: Marja-Liisa Sodervall, Arja Kalapudas, Lauri Kangas, Risto Lammintausta, Pirkko Harkonen, Kalervo Vaananen